Health leaders from organizations such as Oregon Health & Science University and Penn Medicine discussed issues with accessing specialty care at the TIME100 Health Leadership Forum on September 10 in New York City. According to Amy Ronneberg, CEO of NMDP, a global nonprofit connecting patients with lifesaving cell therapies, thousands of patients are not getting referred to transplant centers in a timely manner due to financial and geographical barriers. Dr. Eneida R. Nemecek highlighted that geography is a significant problem for patients who need care, which is a symptom of a larger issue with how health systems are designed. The panelists noted that while there have been advances in specialty care, such as CAR-T therapies, the process of accessing these treatments can be complex and time-consuming.
Written by the local model on 2026-09-11,
using this article's own text rather than the other coverage of the
same event (that is the story summary below).
Story summary
The TIME100 Health Leadership Forum was held on September 10 in New York City, bringing together experts to discuss equity, longevity, and solution-driven care. A panel discussion, "The Access Gap: Expanding Pathways to Life-Saving Care," focused on the issue of patients accessing breakthrough technologies like xenotransplants and novel cancer therapies. Amy Ronneberg, CEO of NMDP, a nonprofit connecting patients with lifesaving cell therapies and transplants, noted that while modern science has solved some access issues, others remain. Specifically, she mentioned that six years ago, the biggest barrier was the lack of donors to match patients. However, now that more patients have found donors, new barriers are emerging. Meanwhile, Shane Jacobson, CEO of the American Cancer Society and the American Cancer Society Cancer Action Network, spoke at a separate panel discussion about the significant strides made in tackling cancer, attributing these advancements to philanthropic investments and federal government funding. He noted that cancer is an "omnipresent" disease, affecting one in three men and women in the US, but emphasized that with continued progress, it may become more manageable.
Written for “Medical Breakthroughs and Reform” on 2026-09-12,
grounded in this article and the 1 other(s) covering the same event.
When there are breakthrough technologies like xenotransplants, or novel cancer therapies, they’re transformative for diseases and conditions once thought incurable—but they can only save lives if the people that need them can access them.
asserted
that → be → them
On September 10, TIME hosted the third annual TIME100 Health Leadership Forum in New York City, bringing together the TIME and TIME100 Health communities to discuss equity, longevity, and solution-driven care.
asserted
TIME → host → equity
The evening featured five expert panels, including The Access Gap: Expanding Pathways to Life-Saving Care.
asserted
evening → feature → Care
Moderated by TIME senior health correspondent Alice Park, the panel invited faculty physicians specializing in cell therapies from Oregon Health & Science University and Penn Medicine to take part in conversation with Amy Ronneberg, chief executive officer of NMDP, a global nonprofit connecting patients with lifesaving cell therapies and transplants.
asserted
panel → moderate → therapies
While modern science has solved some access issues, others still remain.
asserted
others → solve → issues
“If we go back six years, the biggest barrier was the fact that there were not donors to match,” says Ronneberg.
asserted
Ronneberg → go → ?
“As more patients have a donor, we now are facing issues around referral.
asserted
we → have → referral
Thousands of patients are not getting referred to transplant centers in a timely manner, those that are oftentimes are facing major barriers from a financial perspective.”
asserted
that → refer → perspective
Dr. Eneida R. Nemecek, director of Pediatric Cell Therapy and Transplant & Cancer Clinical Research at Oregon Health & Science University, agreed that geography is a big problem for patients who need care.
asserted
who → agree → care
She said it’s a symptom of a bigger problem with the way our health systems have been designed.
asserted
systems → say → way
“When we're designing systems for healthcare, we forget that we're designing the systems for the patient.
asserted
we → design → patient
The system designs the system for itself, and then we try to adjust it to the patient,” Nemecek says.
asserted
Nemecek → design → patient
Because of how specialized CAR-T therapies were designed and tested, there can be natural bottlenecks when it comes to scaling up and disseminating it to a wider audience.
asserted
it → design → audience
Dr. David L. Porter, director of the Center for Cell Therapy and Transplant at Penn Medicine, says that advanced therapies like bone marrow transplants or cellular immunotherapies are developed and largely performed at major academic institutions in big cities, usually as a proof of concept.
asserted
therapies → say → concept
However, swaths of the population in the country do not live near one of these institutions or have to drive hours to one that has both the technology and the expertise.
asserted
that → live → technology
Now, there are seven FDA-approved commercial CAR-T cells, and the manufacturers have no problem receiving cells from collection centers, manufacturing them, and returning them.
asserted
manufacturers → be → them
“The barrier is actually collecting the cells,” Porter says.
asserted
Porter → collect → cells
Additionally, undergoing collection and treatment causes huge displacement in patients and their caregivers’ lives.
asserted
undergoing → undergo → patients
The entire process of treatment and testing can take weeks.
asserted
process → take → weeks
“We have those discussions all the time that people would accept suboptimal therapy and give up the potential for curative therapy because they can’t do that,” Porter says.
asserted
Porter → have → that
“There are an enormous number of initiatives trying to improve, and they move the needle a little bit.”
asserted
they → be → needle
One of these methods is to try to give these therapies in community health centers closer to where the patients are.
asserted
patients → try → centers
Porter and his colleagues recently conducted a pilot study at the University of Pennsylvania with two of their community partners to implement high-end CAR-T cell therapy in a community setting.
asserted
Porter → conduct → setting
Over the course of about a year, they’ve been able to treat over 60 patients who otherwise largely would not have had access because they would not have traveled to a big city for it.
asserted
they → treat → it
With science changing fast and treatment outcomes improving, Ronneberg says that it’s more important than ever to “get the education and awareness out to the community,” and provide them with “funds to travel.”
asserted
it → change → funds
As a cancer survivor herself, Ronneberg recalled having a hard time navigating the process even when she had everything at her fingertips—a husband who’s a doctor, resources from her job at the NMDP.
asserted
who → recall → NMDP
The organization’s focus has moved beyond simply finding donors to now getting patients to the right treatment they need at the right locations, whether that’s an academic center or a community center.
asserted
that → move → locations
To this end, Nemecek and her colleagues have been working on projects like ACCESS Initiative, in partnership with NMDP, in order to start training community centers and equip them with accreditation needed to collect cells.
asserted
Nemecek → work → cells
“With valuable telehealth, with use of technology,” Nemecek says, “that’s really where the future of our field is.”
asserted
future → say → field
The TIME100 Health Leadership Forum was presented by the American Cancer Society, Kite—a Gilead Sciences company, Insulet, Musely, and NMDP.
asserted
Forum → present → Society
